Sangamo BioSciences | SGMO - Operating Expenses


Sangamo BioSciences reported $33.87M in Operating Expenses for its fiscal quarter ending in June of 2024.





Operating Expenses Change Date
Alaunos Therapeutics USD 1.19M 148K Sep/2025
Alnylam Pharmaceuticals USD 965.32M 84.27M Dec/2025
Alterity Therapeutics Limited AUD 7.78M 3M Jun/2023
Amgen USD 5.9B 773M Dec/2025
Bayer EUR 10.33B 126M Dec/2025
BioCryst Pharmaceuticals USD 146.17M 534.06M Dec/2025
Biogen USD 1.88B 81.4M Sep/2025
BioMarin Pharmaceutical USD 676.18M 131.65M Dec/2025
Cipla INR 60.98B 1.06B Dec/2025
Clal Biotechnology ILS 5.15M 9.47M Dec/2022
Compugen USD 11.29M 1.51M Dec/2025
CSL USD 5.7B 2.82B Dec/2025
Gilead Sciences USD 4.96B 707M Dec/2025
GlaxoSmithKline GBP 7.18B 1.42B Dec/2025
Grifols EUR 1.99B 217.4M Dec/2025
Ionis Pharmaceuticals USD 418M 101.1M Dec/2025
J&J USD 18.97B 2.38B Dec/2025
Karyopharm Therapeutics USD 61.82M 3.24M Dec/2024
Merck USD 10.16B 558M Dec/2025
Novartis USD 9.8B 61M Dec/2025
Omeros USD 59.16M 20.13M Jun/2024
Pfizer USD 12.91B 79.89B Dec/2025
Roche Holding CHF 21.01B 10.84B Dec/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sanofi EUR 10.51B 1.21B Dec/2025
Sarepta Therapeutics USD 853.02M 390.78M Dec/2025
Tectonic Therapeutic USD 21.52M 374K Dec/2025
Ultragenyx Pharmaceutical USD 321M 9.82M Dec/2025
Vertex Pharmaceuticals USD 1.93B 89.1M Dec/2025